Pharma Industry
Industry: Email Alert RSS FeedGeneric versions of Periostat still available
Journal of Drugs in Dermatology, Sept-Oct, 2005
CollaGenex Pharmaceuticals, Inc., announced that the United States District Court for the Eastern District of New York has denied its motion seeking a temporary restraining order and a preliminary injunction against pharmaceutical companies distributing generic versions of its drug Periostat (doxycycline 20 mg).
Most RecentPharma Articles
- Noven's Brandt Pockets $2.4M in Hisamitsu Buy, Just 15 Months Into the Job
- Analysts Rain on Lilly's Effient Parade; 70% of Sales Go Generic After 2011
- Doctors May Not All Be Big Pharma's Friends in Healthcare Reform Debate
- UPDATED: Pfizer Accused of "Bribe" to Stave Off Price Control Law in Philippines
- Merck KGaA on Cancer Vaccines: We're Not Crazy, Just Convinced
- More »
Therefore, IVAX Pharmaceuticals, Inc., and CorePharma LLC are still able to market their generic equivalents of this drug. CollaGenex, Inc., reports that it will continue its attempts to seek compensation for lost profits as a consequence of the presence of generic versions of Periostat available on the market.
Brought to you by CBS MoneyWatch.com
- 10 Best Places to Retire
- Companies with the Best 401(k) Plans
- Most Important Document for Your Heirs? It's Not Your Will
- Video: Should You Expect to Retire Rich?
- Over 50? Here's How to Get (and Keep) a Great Job
Most Recent Health Articles
Most Recent Health Publications
Most Popular Health Articles
- Detox in 7 days: a detoux diet can help you shed up to 10 pounds and leave you feeling terrific. Our weeklong plan shows you how to lose the weight and keep it off - Cover story
- All about nightshades: explore the hidden hazards of your favorite food with macrobiotic nutritionist Lino Stanchich
- La anemia falciforme - causas y tratamiento
- The sour truth about apple cider vinegar - evaluation of therapeutic use
- Treat sinusitis naturally: breath easy and relieve sinus pressure with these remedies - Quick Fixes and Long-Term Solutions

